NCT# ClinicalTrials.gov

Related by string. * : ClinicalTrials.gov identifier NCT# . ClinicalTrials.gov Identifier NCT# . study identifier NCT# . NCT# / http:/www.clinicaltrials.gov . www.clinicaltrials.gov . clinicaltrials.gov . www.ClinicalTrials.gov : NIH registry www.clinicaltrials.gov . Search PubMed Clinicaltrials.gov . ClinicalTrials.gov . Clinicaltrials.gov * number NCT# ClinicalTrials.gov *

Related by context. Frequent words. (Click for all words.) 64 NCT# 63 randomized Phase III 62 prospective observational 62 Thrombolysis 62 ClinicalTrials.gov 62 multicenter randomized 61 substudy 61 prospective multicenter 61 multicenter randomized double 61 placebo controlled clinical 61 ALLHAT 60 Phase III randomized 60 Percutaneous Coronary Intervention 60 multicenter clinical 60 multicentre 60 Phase Ib clinical 60 randomized controlled 60 http:/www.clinicaltrials.gov 59 NSABP 59 PRECiSE 59 randomized controlled clinical 59 PREZISTA r 59 Multicenter 59 active comparator 59 placebo controlled Phase 59 Rosuvastatin 58 double blinded placebo 58 Pivotal Trial 58 KRN# 58 Pivotal Phase III 58 SWOG 58 label multicenter 58 Cardiovascular Risk 58 multicenter 58 placebo controlled randomized 58 Phase III Clinical Trial 58 Acute Myocardial Infarction 58 irbesartan 57 pertuzumab 57 Pivotal Phase 57 TRITON TIMI 57 EORTC 57 randomized clinical 57 prospective randomized controlled 57 neoadjuvant 57 tanespimycin 57 Arch Intern Med 57 HSCT 57 XELOX 57 RTOG 57 Pioglitazone 57 Taxotere ® 56 SABCS 56 atherothrombosis 56 BLOSSOM 56 lipid lowering drugs 56 SPIRIT III 56 J Clin Oncol 56 mRCC 56 subgroup analyzes 56 Monotherapy 56 TYKERB 56 GSK# [001] 56 Pharmacokinetic 56 heavily pretreated 56 prospective randomized 56 relapsed refractory multiple myeloma 56 Meta Analysis 56 Gemzar ® 56 Solid Tumors 56 liver transplant recipients 56 blinded placebo controlled 56 tipranavir 56 Ischemic 56 noninferiority 55 RADIANT 55 HALTS 55 evaluable 55 Secondary endpoints 55 retrospective cohort study 55 Myocardial Infarction 55 acute coronary syndromes ACS 55 Phase 1b clinical 55 placebo controlled trials 55 secondary efficacy endpoints 55 tolvaptan 55 PROPEL trial 55 Phase Ia 55 Gynecologic Oncology Group 55 randomized 55 coronary revascularization 55 ATTRACT 55 tocilizumab 55 glatiramer acetate 55 lacosamide 55 J Am Coll 54 Phase 1b trial 54 Carotid 54 placebo controlled studies 54 clinicaltrials.gov 54 Amrubicin

Back to home page